Fiasp de-listed from PBS

Diabetes patients are facing a significant increase in the cost of their medication following the government’s decision to remove Fiasp (insulin aspart injection) from the Pharmaceutical Benefits Scheme (PBS)  Senator Anne Ruston, the Coalition’s shadow health minister, said the de-listing of the fast-acting insulin would see patients’ out of pocket costs jump from a maximum